In a complementary study, transgenic mammary gland overexpression of RANK was shown to exacerbate medroxyprogesterone acetate-induced mammary tumor formation, and that systemic RANKL blockade resulted in a 90% reduction in hormone-induced mammary tumor onset (120, 121). This evidence concerns the gene TNFRSF11A and breast cancer.